• In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net income, raised its full-year 2026 revenue guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurchase program covering 8.7% of shares, affirmed a US$0.12 quarterly dividend, and highlighted recent FDA approval of its low-estrogen Gwyn Lo contraceptive patch.
• Taken together, these updates point to a company using cash flows to retire shares and sustain dividends while adding a new women’s health product that could broaden its portfolio mix.
• Now we’ll explore how the completed US$1.15 billion buyback reshapes Viatris’ investment narrative and interacts with its updated 2026 outlook.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Viatris Investment Narrative Recap

To own Viatris, you have to believe its large off-patent portfolio can keep throwing off enough cash to manage debt, fund select new products and return capital, despite pricing and regulatory pressures. The latest results and modest guidance raise do not materially change the near term catalyst, which is execution on new product launches like Gwyn Lo, or the key risk, which is ongoing pressure on generics pricing and margins in core markets.

Among the recent announcements, the completion of the US$1,150.09 million buyback, retiring about 8.7% of shares, stands out alongside the updated 2026 revenue range. For investors, that combination ties the near term outlook directly to per share outcomes, since any future earnings and cash flows are now spread over a smaller share base, intensifying the importance of how Viatris manages pricing pressure and pipeline execution from here.

But against this backdrop of higher guidance and buybacks, the risk that ongoing generic price pressure and drug pricing reforms could still weigh on Viatris’ core cash engine is something investors should be aware of...

Viatris’ narrative projects $15.6 billion revenue and $765.4 million earnings by 2029.

Uncover how Viatris' forecasts yield a $18.50 fair value, a 13% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected about US$15.6 billion of revenue and roughly US$1.9 billion of earnings by 2029, so if you focus on regulatory and pricing risks you may see this new guidance and buyback either strengthening that upbeat view or challenging it, which is why it helps to compare several viewpoints before deciding what you believe about Viatris.

Explore 6 other fair value estimates on Viatris - why the stock might be worth just $18.50!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Viatris research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Viatris research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viatris' overall financial health at a glance.

Contemplating Other Strategies?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find 52 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.